Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.

NCT01054170 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01054170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01054170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
November 30, 2010
Enrollment
52 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)